Every 424B that CAMP4 Therapeutics Corporation (CAMP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CAMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAMP filings page.
CAMP4 Therapeutics Corporation has registered for resale up to 10,795,804 shares of common stock and 21,925,368 shares issuable upon exercise of 2026 pre-funded warrants, all held by existing investors from a prior private placement. The company is not selling any shares and will not receive proceeds from resale, but may receive cash only if the pre-funded warrants are exercised.
CAMP4 is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics, led by CMP-002 for SYNGAP1-related disorder, with Phase 1/2 clinical trials cleared in Australia. The second closing of its private placement on August 3, 2026 raised gross proceeds of $50.1 million via common stock and 2026 pre-funded warrants. The registered shares represent about 38.6% of outstanding common stock as of August 3, 2026, which the company notes could pressure the share price if sold in volume. Any cash proceeds from warrant exercises are intended to fund CMP-002 development and general corporate purposes.
CAMP4 Therapeutics Corporation is offering 5,000,000 shares of its common stock at $6.00 per share, a primary offering that will provide approximately $28.0 million in net proceeds. The shares trade on the Nasdaq Global Market under the symbol “CAMP” and are expected to be delivered on or about December 19, 2025. After the deal, shares outstanding are expected to increase to 51,880,185, meaning existing holders are diluted but the company adds cash it plans to use mainly to advance its RNA-targeting drug pipeline and for general corporate purposes. New investors will see immediate dilution, as the as adjusted net tangible book value is estimated at $1.67 per share compared with the $6.00 purchase price.
CAMP4 Therapeutics is registering up to 33,431,131 shares of common stock for resale by existing investors, including 6,003,758 shares issuable upon exercise of pre-funded warrants. This total consists of 26,717,414 shares issued in a September 11, 2025 private placement (including the pre-funded warrant shares) and 6,713,717 additional shares with piggyback registration rights. The company will not receive proceeds from investor resales, but may receive cash if the 2025 pre-funded warrants, which have a $0.0001 per share exercise price, are exercised for cash.
The private placement raised approximately $50.1 million in gross proceeds at prices around $1.53 per share. As of October 1, 2025, CAMP4 had 46,880,185 shares of common stock outstanding. The prospectus notes that the registered resale shares represent about 69% of outstanding shares, so large sales could pressure the stock price.
CAMP4 is a clinical-stage biotech using its RNA Actuating Platform to upregulate gene expression for genetic diseases, with a lead preclinical program, CMP-002, for SYNGAP1-related neurodevelopmental disorders targeting a Phase 1/2 trial as early as the second half of 2026, and a clinical candidate CMP-001 for urea cycle disorders, where development spending is paused while the company seeks partners.